BIO
Price
$314.46
Change
-$1.92 (-0.61%)
Updated
Jul 24 closing price
Capitalization
8.39B
4 days until earnings call
Intraday BUY SELL Signals
DHR
Price
$191.50
Change
-$1.00 (-0.52%)
Updated
Jul 24 closing price
Capitalization
134.62B
93 days until earnings call
Intraday BUY SELL Signals
MTD
Price
$1327.18
Change
-$4.69 (-0.35%)
Updated
Jul 24 closing price
Capitalization
26.82B
4 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIO or DHR or MTD

BIO vs DHR vs MTD Comparison Chart in %
View a ticker or compare two or three
Jul 20, 2026

Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) vs. Mettler-Toledo (MTD) Stock Comparison

Key Takeaways

  • BIO, DHR, and MTD operate in overlapping life sciences and diagnostics markets, with varying scales and growth profiles.
  • Recent market activity shows DHR posting stronger year-to-date returns compared to BIO and MTD, amid sector-wide pressures in academic and biopharma end markets.
  • MTD delivered solid Q1 2026 sales growth and raised full-year guidance, reflecting resilience in precision instruments.
  • BIO reported modest reported sales gains in Q1 2026 but faced currency-neutral declines, highlighting exposure to challenging academic segments.
  • DHR maintains a larger market capitalization and diversified segments, with upcoming Q2 earnings expected to provide further clarity on diagnostics trends.
  • Relative performance underscores trade-offs between stability in larger peers and potential volatility in smaller, specialized players.

Introduction

Investors and traders focused on the life sciences and diagnostics sector often evaluate BIO, DHR, and MTD together due to their shared exposure to research tools, clinical diagnostics, and precision measurement technologies. This comparison highlights differences in business scale, recent operational results, and market positioning within a competitive healthcare subsector. Professionals seeking diversified exposure or relative value opportunities, as well as those monitoring sector sentiment shifts, may find this analysis relevant for assessing how these stocks have navigated recent market conditions.

BIO Overview and Recent Performance

BIO (Bio-Rad Laboratories) develops and markets products for life science research and clinical diagnostics markets. In recent weeks, the stock has traded in a range influenced by Q1 2026 results showing reported net sales of $592.1 million, up 1.1% year-over-year, though currency-neutral sales declined 4.2%. Operating income improved, but net results reflected one-time items. Market sentiment has reflected ongoing challenges in academic end markets and broader biopharma dynamics, contributing to relatively flat year-to-date performance amid sector headwinds.

DHR Overview and Recent Performance

DHR (Danaher) operates across biotechnology, life sciences, and diagnostics segments, serving biopharma and clinical customers globally. Recent market activity shows the stock benefiting from its diversified portfolio, with year-to-date returns outpacing broader market benchmarks in some periods. The company is scheduled to report Q2 2026 earnings shortly, with analysts anticipating modest revenue growth. Sentiment has been shaped by acquisition activity in diagnostics and steady demand in core areas, supporting a more stable price trajectory compared to smaller peers.

MTD Overview and Recent Performance

MTD (Mettler-Toledo International) provides precision instruments and analytical solutions for laboratory and industrial applications. In recent market activity, the company reported Q1 2026 sales growth of 7% to $947.1 million and raised full-year adjusted earnings guidance, citing strength across regions. Stock performance has reflected these operational updates alongside broader sector trends, with year-to-date gains supported by consistent execution in high-margin product lines. Sentiment remains tied to industrial and research spending patterns.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, only the highest-performing and most suitable ones for current environments earn placement in this section. Available bots feature varied trading styles, strategies, timeframes, and performance statistics, with historical win rates and returns often ranging across different risk profiles. This resource allows traders to explore data-driven approaches tailored to individual preferences. Explore the full selection on the Trending AI Robots page.

Head-to-Head Comparison

Business models differ in scope: DHR offers the broadest diversification across multiple segments, while BIO focuses more narrowly on research and diagnostics tools, and MTD emphasizes precision measurement equipment. Growth drivers include biopharma R&D spending for all three, though MTD has shown stronger recent sales momentum. Recent momentum favors DHR on a year-to-date basis, with BIO lagging amid end-market softness. Risk factors encompass currency fluctuations and academic budget constraints for BIO, integration and cost pressures for DHR, and cyclical industrial demand for MTD. Sector exposure remains concentrated in healthcare tools, with valuation sensitivity varying by market capitalization—larger entities like DHR often exhibit lower beta. Market sentiment reflects cautious optimism tied to earnings visibility across the group.

Tickeron AI Verdict

Based on observable factors such as trend consistency in recent quarters, earnings stability, and relative positioning within the sector, Tickeron’s AI would likely assign a higher probability of near-term favorability to DHR due to its scale, diversified revenue streams, and steadier performance metrics amid mixed industry conditions. MTD presents competitive attributes through guidance raises, while BIO shows more variability. This assessment remains probabilistic and subject to evolving data.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2026
Stock price -- (BIO: $314.46DHR: $191.50MTD: $1327.18)
Brand notoriety: BIO, DHR and MTD are all not notable
DHR and MTD are part of the Medical Specialties industry, and BIO is in the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: BIO: 102%, DHR: 136%, MTD: 90%
Market capitalization -- BIO: $8.39B, DHR: $134.62B, MTD: $26.82B
$DHR [@Medical Specialties] is valued at $134.62B. $MTD’s [@Medical Specialties] market capitalization is $ $26.82B. $BIO [@Medical/Nursing Services] has a market capitalization of $ $8.39B. The market cap for tickers in the [@Medical Specialties] industry ranges from $ $3.82T to $ $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $ $179.51B to $ $0. The average market capitalization across the [@Medical Specialties] industry is $ $17.05B. The average market capitalization across the [@Medical/Nursing Services] industry is $ $5.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and MTD’s FA Score reflects 1 green FA rating(s).

  • BIO’s FA Score: 2 green, 3 red.
  • DHR’s FA Score: 1 green, 4 red.
  • MTD’s FA Score: 1 green, 4 red.
According to our system of comparison, MTD is a better buy in the long-term than BIO, which in turn is a better option than DHR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s), and MTD’s TA Score reflects 5 bullish TA indicator(s).

  • BIO’s TA Score: 5 bullish, 4 bearish.
  • DHR’s TA Score: 4 bullish, 5 bearish.
  • MTD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BIO is a better buy in the short-term than MTD, which in turn is a better option than DHR.

Price Growth

BIO (@Medical/Nursing Services) experienced а +3.32% price change this week, while DHR (@Medical Specialties) price change was -6.05% , and MTD (@Medical Specialties) price fluctuated +1.31% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.

Reported Earning Dates

BIO is expected to report earnings on Jul 30, 2026.

DHR is expected to report earnings on Oct 27, 2026.

MTD is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Medical/Nursing Services (-5.78% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Medical Specialties (-1.55% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DHR($135B) has a higher market cap than MTD($26.8B) and BIO($8.39B). BIO has higher P/E ratio than DHR and MTD: BIO (52.32) vs DHR (34.14) and MTD (31.18). BIO YTD gains are higher at: 3.786 vs. MTD (-4.806) and DHR (-15.994). DHR has higher annual earnings (EBITDA): 7.08B vs. MTD (1.25B) and BIO (440M). BIO has less debt than MTD and DHR: BIO (1.38B) vs MTD (2.23B) and DHR (18.5B). DHR has higher revenues than MTD and BIO: DHR (24.8B) vs MTD (4.09B) and BIO (2.59B).
BIODHRMTD
Capitalization8.39B135B26.8B
EBITDA440M7.08B1.25B
Gain YTD3.786-15.994-4.806
P/E Ratio52.3234.1431.18
Revenue2.59B24.8B4.09B
Total Cash1.57BN/A60.6M
Total Debt1.38B18.5B2.23B
FUNDAMENTALS RATINGS
BIO vs DHR vs MTD: Fundamental Ratings
BIO
DHR
MTD
OUTLOOK RATING
1..100
171846
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
6
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100100
SMR RATING
1..100
90802
PRICE GROWTH RATING
1..100
205648
P/E GROWTH RATING
1..100
117251
SEASONALITY SCORE
1..100
85n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DHR's Valuation (6) in the Medical Specialties industry is significantly better than the same rating for BIO (85) and is significantly better than the same rating for MTD (99). This means that DHR's stock grew significantly faster than BIO’s and significantly faster than MTD’s over the last 12 months.

DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100) and is in the same range as MTD (100). This means that DHR's stock grew similarly to BIO’s and similarly to MTD’s over the last 12 months.

MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for DHR (80) and is significantly better than the same rating for BIO (90). This means that MTD's stock grew significantly faster than DHR’s and significantly faster than BIO’s over the last 12 months.

BIO's Price Growth Rating (20) in the Medical Specialties industry is in the same range as MTD (48) and is somewhat better than the same rating for DHR (56). This means that BIO's stock grew similarly to MTD’s and somewhat faster than DHR’s over the last 12 months.

BIO's P/E Growth Rating (11) in the Medical Specialties industry is somewhat better than the same rating for MTD (51) and is somewhat better than the same rating for DHR (72). This means that BIO's stock grew somewhat faster than MTD’s and somewhat faster than DHR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIODHRMTD
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
46%
Bearish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
61%
Bearish Trend 3 days ago
65%
Momentum
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
66%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
53%
Bullish Trend 3 days ago
58%
Advances
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
54%
Bullish Trend 11 days ago
60%
Declines
ODDS (%)
Bearish Trend 6 days ago
69%
Bearish Trend 6 days ago
61%
Bearish Trend 7 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
54%
Bullish Trend 3 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
BIO
Daily Signal:
Gain/Loss:
DHR
Daily Signal:
Gain/Loss:
MTD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ANGH3.370.17
+5.31%
Anghami Inc
ICFI79.522.43
+3.15%
ICF International
FNB19.050.18
+0.95%
FNB Corp
WFC86.310.12
+0.14%
Wells Fargo & Co
CUB10.81N/A
N/A
Lionheart Holdings

BIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIO
1D Price
Change %
BIO100%
-0.61%
A - BIO
68%
Closely correlated
-0.84%
RVTY - BIO
67%
Closely correlated
-2.39%
DHR - BIO
66%
Loosely correlated
-0.52%
MTD - BIO
64%
Loosely correlated
-0.35%
TMO - BIO
63%
Loosely correlated
-0.71%
More

DHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DHR
1D Price
Change %
DHR100%
-0.52%
TMO - DHR
77%
Closely correlated
-0.71%
A - DHR
73%
Closely correlated
-0.84%
RGEN - DHR
68%
Closely correlated
-4.10%
BIO - DHR
64%
Loosely correlated
-0.61%
BRKR - DHR
58%
Loosely correlated
-2.74%
More